Survival in melanoma brain metastases in the era of novel systemic therapies

BACKGROUND: Melanoma brain metastases (MBMs) have historically poor overall survival (OS). Recently introduced systemic anticancer therapies (SACTs), namely targeted therapies such as BRAF inhibitors and immunotherapy, to control advanced disease have shown improved survival. Today, increasingly agg...

Descripción completa

Detalles Bibliográficos
Autores principales: Merola, Joseph P, Ocen, Joanita, Kumar, Satish, Powell, James, Hayhurst, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764504/
https://www.ncbi.nlm.nih.gov/pubmed/33392503
http://dx.doi.org/10.1093/noajnl/vdaa144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764504/
https://www.ncbi.nlm.nih.gov/pubmed/33392503
http://dx.doi.org/10.1093/noajnl/vdaa144

Ejemplares similares